First Patient Dosed in Phase 2 Clinical Trial of Vedanta’s VE202 for the Treatment of Ulcerative Colitis
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient in the Phase 2 COLLECTiVE202 clinical study of VE202 […]
